[Skip to Navigation]
May 9, 2019

Fundus Hypopigmentation and Loss of Choroidal Nevi Pigmentation Associated With Nivolumab

Author Affiliations
  • 1Department of Ophthalmology and Visual Sciences, Medical College of Wisconsin, Milwaukee
  • 2Morrison Eye Clinic SC, Delavan, Wisconsin
JAMA Ophthalmol. 2019;137(7):851-853. doi:10.1001/jamaophthalmol.2019.0970

A 59-year-old white man without ocular symptoms presented for annual follow-up of bilateral choroidal nevi (Figure 1A and B). Ten years before this visit, he had undergone complete wide excision of a cutaneous melanoma of the left forearm, along with a negative biopsy of sentinel lymph nodes. One year before the visit, he had developed a left axillary mass; a biopsy was positive for melanoma. He had received 4 infusions of 240 mg of nivolumab at 2-week intervals, after which the drug was discontinued because of elevated liver function test results, hypothyroidism, xerostomia, and dizziness. He started taking levothyroxine and continued taking aspirin, atenolol, and atorvastatin.

Add or change institution